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Introduction
Food allergy affects approximately 3.9% of US children with a 
reported increase in prevalence of 18% from 1997–2007.1 Other 
allergic conditions such as asthma, allergic rhinitis and atopic der-
matitis have increased in prevalence over the same time period.2,3 
The explanation for this rise in allergic disease is unknown and 
may reflect a combination of genetic and environmental factors. 
The major allergenic foods that account for about 90% of food 
allergies in the US are milk, egg, peanut, tree nuts, soybeans, 
wheat, fish and shellfish.4
Although there are different forms of food allergy, this review 
will focus specifically on IgE mediated food allergy, which results 
in symptoms immediately after ingestion of the offending anti-
gen. IgE mediated food allergy is thought to result from a defect 
in oral tolerance, although the mechanism of this breakdown is 
not completely understood. Oral tolerance is the process by which 
the mucosal immune system suppresses immunity to benign 
allergens encountered in the gastrointestinal tract.5 This process 
involves multiple mechanisms including deletion of antigen-
specific T cells, induction of anergy (non-response) in antigen-
specific T cells and production of regulatory T cells (Tregs).6,7
With a defect in oral tolerance, patients develop a Th2-
predominant allergen-specific immune response with the pro-
duction of immunoglobulin IgE antibodies specific to the food 
allergen. Th2 cells secrete interleukin (IL)-4 and IL-13, which 
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Food allergy affects 3.9% of uS children and is increasing in 
prevalence. The current standard of care involves avoidance 
of the triggering food and treatment for accidental ingestions. 
while there is no current curative treatment, there are a 
number of therapeutic strategies under investigation. allergen 
specific therapies include oral and sublingual immunotherapy 
with native food protein as well as recombinant food proteins. 
allergen non-specific therapies include a chinese herbal 
formula (FaHF-2) and the use of anti-Ige monoclonal antibody 
therapy. although none of these treatments are ready for 
clinical use, these therapeutic strategies present promising 
options for the future of food allergy.
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encourage the production of IgE by B cells. Once the offending 
food allergen is ingested, IgE bound to mast cells in mucosal tis-
sues can recognize the antigen and degranulate, releasing media-
tors such as histamine, leukotrienes and prostaglandins. These 
mediators lead to allergic symptoms, including anaphylaxis.
Patients with food allergy remain at risk of a significant life-
threatening reaction if the antigen is ingested. While many chil-
dren with egg, milk, wheat and soy allergy will outgrow their 
food allergy, the majority of patients affected with peanut or 
seafood allergy will not. Without a curative treatment, the cur-
rent standard of care focuses on strict avoidance of the offend-
ing dietary protein. Despite education on avoidance of triggering 
foods protein, many patients will still have accidental ingestions. 
Due to this risk of accidental ingestions, patients are educated 
on how to manage anaphylactic reactions and are instructed to 
carry epinephrine at all times. Unfortunately, food allergy is the 
most common cause of anaphylaxis evaluated in the emergency 
department8 and occasionally results in fatalities with more than 
90% of deaths in the US caused by reactions to peanuts or tree 
nuts.9,10 Given the increasing prevalence of food allergy and the 
high risk for accidental reactions, there has been a focus on new 
therapies to treat food allergic patients.
The use of allergen specific and allergen non-specific thera-
pies has been explored recently to treat food allergy patients 
and reduce the risk of life threatening reactions. Allergen spe-
cific therapies rely on either gradually increasing exposure to an 
unmodified allergen or administration of a modified allergen 
in an attempt to induce oral tolerance. Non-specific therapies 
rely on broad immunologic changes to decrease the pathogenic 
response to the allergen.
Allergen Specific Therapies
Immunotherapy for food allergy. Allergen immunotherapy 
involves the treatment of allergic disease by modulating the 
immune response.11 Most trials have assessed desensitization, 
a temporary loss of reactivity to the protein due to continuous 
exposure. Few studies have demonstrated tolerance, which is 
defined as a permanent immunologic non-response to the offend-
ing allergen and can only be assessed by removing the allergen 
from the diet for a period of time prior to challenge. In this con-
text, the ultimate goal of immunotherapy for food allergy is to 
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the study, including patients initially on placebo treatment who 
were offered open label treatment following their post-treatment 
challenge. Milk specific IgE levels did not change significantly 
in either the treatment or placebo groups, however milk spe-
cific IgG4 levels did increase on active treatment. Food specific 
IgG
4
 subclass antibodies are proposed to have a protective or 
blocking function.21,22 A recent meta-analysis focused on OIT 
for IgE-mediated cow’s milk allergy evaluated five randomized 
controlled trials and five observational studies.23 Two hundred 
eighteen patients in the randomized controlled trials demon-
strated the likelihood of tolerating 150 mL of cow’s milk and the 
ability to eat dairy and milk-containing products was ten times 
higher in the OIT group as compared with elimination diet alone 
(95% CI: 4.1–24.2) suggesting efficacy in desensitizing patients 
through the use of OIT.
Egg OIT. Egg OIT published studies have been largely limited 
to open label clinical trials. In an open, uncontrolled study of 
egg OIT in children with egg allergy, seven children underwent 
a 24 mo egg OIT protocol involving modified rush, build-up and 
maintenance phase dosing consisting of 300 mg of powdered egg 
white.24 All patients were able to tolerate significantly more egg 
protein at the post-therapy challenge. However, after following 
an egg restricted diet for 3–4 mo at the completion of the study, 
only two out of four patients were able to tolerate the doses previ-
ously tolerated at the completion of the study suggesting toler-
ance was obtained in only two of these patients.
Based on the results of this proof-of-concept egg OIT trial, 
the authors hypothesized that further dose escalation would 
improve OIT outcomes. Six patients completed a protocol with a 
maintenance phase consisting of conditional step-wise increases 
every 4 mo up to a maximum of 3,600 mg of egg white protein.25 
Maintenance doses were only increased if egg specific IgE lev-
els were found to be greater than 2 kU/L. Once the egg specific 
IgE level was below 2 kU/L, a DBPCFC was performed. All six 
patients demonstrated a decrease in skin prick test wheal diam-
eter and egg specific IgE levels. All six patients passed a DBPCFC 
one month after stopping OIT. None of the egg OIT studies 
included randomization or a placebo control, limiting interpreta-
tion of the results, as it is possible that these children naturally 
outgrew their allergy.
A multi-center randomized, double-blind, placebo-controlled 
trial of egg OIT is currently ongoing (Oral Immunotherapy 
for Childhood Egg Allergy; clinicaltrials.gov #NCT00461097) 
through the Consortium of Food Allergy Research. Following 
an initial escalation, build-up and maintenance (2000 mg of egg 
white) phase, 30/40 (75%) patients were desensitized at 22 mo.26 
Egg OIT was discontinued for 6–8 weeks and another OFC was 
conducted. 11/40 (27.5%) patients passed this OFC and were 
considered tolerant. A smaller skin prick test size at 22 mo was 
correlated with desensitization and tolerance in this study.
Peanut OIT. Following preliminary open label OIT trials, a 
double-blind, placebo-controlled study was conducted at Duke 
University Medical Center and Arkansas Children’s Hospital 
consisting of 28 children with peanut allergy.27 This protocol 
consisted of initial escalation day, a build-up dosing phase for 
44 weeks and maintenance dosing phase of 4000 mg for 1 mo 
Subcutaneous immune therapy. Subcutaneous immunother-
apy (SCIT) has been used for over a century and is a successful 
therapeutic approach for treatment of hay fever and hymenoptera 
sensitivity.12-14 Treatment is associated with an initial increase 
in allergen-specific IgE followed by eventual decrease and an 
increase in allergen-specific IgG4. The first report of success-
ful SCIT for food allergy was published in 1930. Interestingly, 
no new reports appeared until the early 1990s when SCIT for 
peanut allergy was reported. In that study, three treated subjects 
displayed a 67–100% decrease in symptoms induced by double-
blind, placebo-controlled food challenge (DBPCFC).15 These 
subjects also demonstrated a 2–5-log reduction in end-point skin 
prick test reactivity to peanut. One placebo-treated subject died 
of anaphylaxis following accidental administration of peanut 
extract due to a pharmacy formulation error, resulting in prema-
ture termination of the study.
In another study, six subjects were treated up to a maintenance 
dose of 0.5 ml of 1:100 wt/vol peanut extract and six were fol-
lowed as an untreated control group for 12 mo.16 At the end of 12 
mo, the six treated subjects demonstrated increased tolerance to 
double-blind, placebo-controlled peanut challenge and decreased 
skin prick test reactivity to peanut. The untreated controls had 
no improvement in those parameters. Significant adverse events 
were recorded in the treatment group even during maintenance 
injections, suggesting that this may be an unfavorable treatment 
approach. 
Oral immunotherapy. Oral immunotherapy (OIT) for food 
allergy dates back to 1908, when Schofield successfully used cap-
sules of increasing amounts of raw egg to desensitize a 13 year-old 
boy with egg allergy.17 Subsequently, several studies using similar 
oral immunotherapy methods provided evidence that successful 
desensitization to milk, egg, fish and fruit is possible.18,19
Recently, OIT has been used for milk, egg and peanut allergy 
(Table 1). These trials have used widely differing dosing regi-
mens and variable outcome criteria. Typically, oral immunother-
apy protocols begin with an initial escalation day consisting of 
increasing doses of the food allergen (mixed with a food vehicle) 
until the subject has symptoms. Following the initial escalation 
day, the patient is begun on a therapy using the previously deter-
mined highest tolerated dose with a build-up period of dosing 
consisting of increasing doses of the offending allergen protein. 
These build-up doses are typically given for the first time in a 
clinical setting with home dosing continuing daily until the next 
increased dose. Once the subject has reached the goal mainte-
nance dose for the trial, this daily dose is continued for a period 
of time, usually several weeks to months, followed by a DBPCFC.
Cow’s milk OIT. Following Schofield’s report, interval tri-
als were conducted examining the efficacy of OIT in random-
ized clinical trials but the first double-blind, placebo-controlled 
report of OIT was not until 100 years following Schofield’s 
report when Skripak et al. randomized 20 children to daily cow’s 
milk or placebo therapy for a total of 13 weeks of treatment.20 
An entry DBPCFC established a threshold of reactivity, which 
was then compared with a post-therapy challenge to assess clini-
cal desensitization. Subjects in the milk OIT group were able to 
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patients requiring epinephrine dosing. 3.5% of total home doses 
of peanut OIT were associated with an adverse reaction including 
upper respiratory tract symptoms accounting for 1.2% and skin 
symptoms accounting for 1.1%. Two subjects out of 28 enrolled 
patients each received epinephrine once during the course of the 
trial following home doses.
Although asthma has clearly been identified as a risk factor 
for respiratory reaction,28 other risk factors for adverse reactions 
have emerged through the course of OIT studies. Varshney et 
al. reported on five patterns associated with an increased risk of 
reaction to previously tolerated dose of peanut OIT including 
(1) concurrent illness, (2) sub-optimally controlled asthma, (3) 
timing of dose administration after food ingestion, (4) physical 
exertion after dosing and (5) dosing during menses.29 As these 
risk factors emerged throughout the course of clinical trials, 
researchers modified their recommendations to address these risk 
followed by the first OFC at week 48. During the DBPCFC, 
all 16 peanut OIT patients completing the protocol were able 
to ingest the maximum cumulative dose of 5,000 mg (approxi-
mately 20 peanuts). The median cumulative dose tolerated by the 
nine placebo patients was 280 mg with a range of 0–1,900 mg. 
The peanut OIT patients showed reductions in SPT size, IL-5 
and IL-13 with increases in IgG4 and FoxP3 regulatory T cells 
while these changes were not seen in patients receiving placebo.
Safety of OIT. In a comprehensive analysis of adverse reac-
tions in one peanut OIT trial, initial escalation day symptoms 
included upper respiratory tract symptoms (79%) and abdominal 
(68%) affecting the majority of patients.28 Symptoms rated as 
severe only occurred in the cutaneous category although mild 
and moderate symptoms were common. With escalations, 15% 
of patients required epinephrine. Reactions associated with 
build-up doses were less common, occurring in 46% with no 
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all patients able to tolerate higher 
amounts of egg protein; 2/4 
patients reacted to subsequent 
challenge 3 mo off treatment
no change in Ige; ↑ IgG 24
Vickery egg OIT open, treatment only
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month after stopping OIT







all patients on OIT able to  
tolerate maximum dose (5000mg) 
vs. median cumulative dose of 
280 in placebo patients
↓skin prick test size, IL-5 
and IL-13; ↑ in IgG4 and 







Significant increase in mean 
quantity of hazelnut ingested to 
provoke symptoms in the  
treatment group with a  
non-significant increase seen in 
placebo group





Treatment group able to ingest 
20x more peanut protein than 
placebo group
↓ skin prick test size; 
initial rise in Ige fol-









Treatment group able to tolerate 
significantly higher amount of 
peach (3–9 fold increase)












Highest drug dose group with 
a signficantly higher threshold 
























1482 Human Vaccines & Immunotherapeutics Volume 8 Issue 10
vegetables in pollen sensitized individuals. Given that pollen 
allergen is responsible for the cross reactivity with food allergens 
in OAS, sublingual and subcutaneous immunotherapy have been 
tried. Since the early positive case report of fresh fruit tolerance 
after a year of pollen immunotherapy reported by Kelso et al. 
many studies have examined the effects of immunotherapy on 
OAS and the results have been mixed.
Randomized clinical trials of birch pollen immunotherapy in 
patients with apple allergy suggest that a subset of birch allergic 
patients with apple allergy show improvement in apple tolerance 
after SCIT.34-36 However, one trial of sublingual immunotherapy 
for birch pollen allergy did not show efficacy for alleviating OAS 
symptoms.37 In a small study comparing injection and sublin-
gual forms of immunotherapy for OAS, complete tolerance to 
raw apple was achieved in two of eight and one of seven patients 
receiving injection and SLIT, respectively.38 Also, an increase in 
the provocative dose was found in three of the SCIT-treated and 
two of the SLIT-treated patients.
Hence, immunotherapy for treatment of oral allergy syn-
drome appears to benefit a subset of patients only.
Modified recombinant vaccines. Immunotherapy with modi-
fied recombinant proteins is an attractive approach that should 
reduce the incidence of adverse effects. While these recombinant 
food proteins retain the ability to generate a T-cell response, they 
have a reduced IgE binding capacity.39 The modified food aller-
gens can be combined with bacterial adjuvants to enhance the 
Th1 and Treg skewing effects and decrease the Th2 effect.
Heat-killed Escherichia coli producing engineered (mutated) 
recombinant peanut proteins have been shown to induce long-
term “downregulation” of peanut hypersensitivity in a murine 
model of peanut allergy.40
An ongoing clinical trial at Johns Hopkins University and 
Mount Sinai Medical Center is evaluating the safety and side 
effects of a product containing recombinant modified peanut 
proteins (EMP-123) in healthy and peanut-allergic participants 
(Peanut Allergy Vaccine Study in Healthy and Peanut Allergic 
Adults; clinicaltrials.gov #NCT00850668).
Promising allergen specific therapies. Several additional 
approaches have been evaluated in animal models and are very 
promising. Synthetic peptides representing T-cell epitopes of food 
allergens have been shown to induce milder allergic reactions in 
murine models of peanut allergy and egg allergy.41,42 Plasmid 
DNA containing a recombinant peanut antigen (Arah2), was 
shown to modify the immune system in mice and protect against 
food allergen-induced hypersensitivity.43 While both approaches 
are promising in murine models, safety, optimal dosage and effi-
cacy remain to be determined in humans.
Allergen Non-specific Therapies
FAHF-2. An herbal formula based on traditional Chinese medi-
cine, consisting of nine herbs, has been shown to be an effective 
treatment in preventing anaphylaxis in murine models of peanut 
allergy.44 Mice allergic to peanut treated with FAHF-2 for 7 weeks 
were challenged post-therapy. After challenge, all sham treated 
mice developed signs of severe anaphylaxis while no signs of 
factors. Although OIT is generally well tolerated, it is important 
to note that these risks exist and understand that OIT is still 
under investigation to determine safety and efficacy prior to use 
in the clinical setting.
Sublingual immunotherapy (SLIT). Sublingual immuno-
therapy involves the administration of small amounts (micro-
grams to milligrams) of the allergen extract under the tongue. 
The first randomized double blind placebo controlled study 
using sublingual immunotherapy included 22 patients with 
hazelnut allergy.30 Although all patients were skin prick test 
positive to hazelnut, the reported symptoms following ingestion 
included approximately 55% of patients reporting oral allergy 
syndrome as opposed to anaphylaxis or urticaria/angioedema. 
After 8–12 weeks of treatment, DBPCFC resulted in a significant 
increase in the mean quantity of hazelnut provoking symptoms 
increase from 2.29 g to 11.56 g in the active group (p = 0.02) 
and a non-significant increase from 3.49 to 4.14 g in the placebo 
group. Improvements were seen in patients with history of local 
symptoms as well as those with history of systemic symptoms. 
Systemic reactions were observed in 0.2% of doses and were only 
seen with build-up dosing, requiring only antihistamines for con-
trol. Local reactions, mostly in the form of immediate oral itch-
ing were observed in 7.4% of doses.
In the first double-blind, placebo-controlled trial for peanut 
allergy, 18 children completed 6 mo of dose escalation and 6 mo 
of maintenance dosing with 2,000 μg of peanut protein.31 At the 
conclusion of the trial, the treatment group was able to ingest 20 
times more peanut protein than the placebo group. Decreased 
skin prick test wheal size was only seen in the treatment group. 
Peanut specific IgE levels increased steadily over the initial 4 
mo and then steadily decreased over the remaining 8 mo and 
an increase in peanut specific IgG4 levels over 12 mo were seen 
in the treatment group. Side effects in the treatment group were 
primarily oropharyngeal (9.3% of doses), which were also seen in 
the placebo group (1.5%).
Additionally, a randomized double-blind, placebo-controlled 
SLIT trial was conducted for peach allergy.32 49 patients com-
pleted the 6 mo SLIT trial (33 on active treatment, 16 on pla-
cebo). The active group tolerated a significantly higher amount of 
peach (3–9 fold increase) with a decrease in SPT and significant 
increase in peach specific IgE and IgG4. The placebo group dem-
onstrated no significant changes. Side effects consisting of local 
reactions (mostly oral symptoms) were common in the active 
treatment group during the build-up phase. Mild systemic reac-
tions were seen in both the active treatment and placebo groups 
with roughly the same frequency (13.5% in the active group and 
16.7% in the placebo group) and subsided spontaneously or with 
antihistamines.
These positive results suggest successful desensitization with 
SLIT for three different food allergies. Safety reporting in these 
three trials reveals SLIT to be a safe therapy with the most com-
mon side effect consisting of local oropharyngeal symptoms.
Immunotherapy with pollen allergens. The oral allergy syn-
drome (OAS) is characterized by an immunoglobulin E (IgE) 
mediated immediate hypersensitivity reaction limited to the 
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increase with desensitization; consistent with their known block-
ing function,21,22 however these increases have not yielded cut-
off values associated with successful desensitization induction. 
While antigen specific FoxP3 T regulatory subsets increase with 
the attainment of tolerance,48 these levels have not been assessed 
in many of the food allergy trials. In the studies which evalu-
ate these levels in conjunction with additional immunologic and 
clinical outcome measures, allergen specific FoxP3 Tregs increase 
with successful desensitization, suggesting this may be useful 
marker for efficacy in the future.27,31 However, this remains a 
research tool without established values for efficacy. Currently, 
the gold standard for measure of efficacy is the DBPCFC.
Conclusions
Food allergy is an increasingly prevalent disorder with no cura-
tive therapy. Due to the high rate of accidental exposures, there 
is an urgent need to develop effective and safe therapies. While 
OIT and SLIT have been studied for several years with encourag-
ing results, we still do not know if they can achieve a permanent 
state of tolerance. Additionally, side effects may limit the utility 
of this treatment to the research setting. Other therapies are in 
the initial stages of investigation but show promise for long-term 
treatments. As with immunotherapy, safety will continue to be a 
concern. Currently, the standard of care remains avoidance and 
immediate access to epinephrine, however these promising thera-
pies give us hope for the future treatment of patients with food 
allergy.
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anaphylaxis were seen in mice treated with FAHF-2. These protec-
tive effects continued for up to 6 mo following therapy suggesting 
a long-term immunologic effect.44,45 Based on multiple immu-
nomodulatory effects seen, including a dose dependent decrease 
in Th2 cytokine production with an increased interferon-γ, it 
is thought to be a general immunosuppressive agent.45 Based on 
these promising results, FAHF-2 is now in clinical trials, phase 
II in patients aged 12–45 y old with allergies to nuts, fish and/or 
shellfish (Therapeutic Effect of Chinese Herbal Medicine on Food 
Allergy (FAHF-2); clinicaltrials.gov #NCT00602160).
Anti-IgE therapy. Recombinant humanized monoclonal anti-
IgE treatment has been suggested as a therapy for food allergy. 
A double-blind, randomized trial was performed in 84 peanut 
allergic patients in which patients either received Hu-901 or pla-
cebo once a month for four months.46 Patients were administered 
varying doses of the drug with results indicating the highest dose 
(450 mg) elicited the greatest increase in median dose tolerated 
from 178 mg to 2.8 g of peanut protein. In this group, 25% of the 
patients had improvement whereas 25% had no change in their 
reactivity, suggesting variability in response to anti-IgE therapy. 
Incidences of local and systemic reactions were similar between 
the active treatment and placebo group. Hu-901 was not selected 
for further clinical development; however studies with an alter-
native humanized anti-IgE molecule, omalizumab (Xolair; 
Genentech), have been initiated.
A controlled trial of omalizumab in patients with peanut 
allergy was terminated because of 2 severe anaphylactic reactions 
that occurred during the initial peanut DBPCFC.47 Twenty-six 
patients had been randomized 2:1 to omalizumab or placebo and 
completed 24 weeks of therapy followed by a second DBPCFC 
by the time the study was terminated. The patients in the omali-
zumab group had a greater increase in tolerability of peanut pro-
tein than the placebo group (p = 0.054).
Combining omalizumab and OIT has been initiated as a ther-
apy for cow’s milk allergy and peanut allergy (Omalizumab with 
Oral Food Immunotherapy in Children and Adults With Food 
Allergies Open Label Safety Study in a Single Center; clinicaltri-
als.gov #NCT01510626 and Peanut Oral Immunotherapy and 
Anti-Immunoglobulin E (IgE) for Peanut Allergy; clinicaltrials.
gov #NCT00932282). This combination has been proposed to 
decrease adverse reactions to immunotherapy and improve out-
comes. No data from controlled clinical trials has been published 
to date.
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